| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Amyotrophic Lateral Sclerosis | 32 | 2024 | 1481 | 2.540 |
Why?
|
| Parkinson Disease | 25 | 2024 | 2886 | 2.260 |
Why?
|
| Uric Acid | 14 | 2023 | 805 | 1.760 |
Why?
|
| Down Syndrome | 8 | 2022 | 916 | 1.020 |
Why?
|
| Neurofibromatoses | 7 | 2024 | 303 | 0.930 |
Why?
|
| Inosine | 8 | 2023 | 129 | 0.780 |
Why?
|
| Tai Ji | 6 | 2022 | 291 | 0.700 |
Why?
|
| Mind-Body Therapies | 7 | 2024 | 294 | 0.600 |
Why?
|
| Disease Progression | 17 | 2024 | 13646 | 0.590 |
Why?
|
| Sleep Apnea, Obstructive | 4 | 2022 | 1897 | 0.490 |
Why?
|
| Clinical Trials as Topic | 9 | 2024 | 8048 | 0.480 |
Why?
|
| Quality of Life | 23 | 2024 | 13485 | 0.470 |
Why?
|
| Telemedicine | 7 | 2020 | 3110 | 0.470 |
Why?
|
| Double-Blind Method | 31 | 2024 | 12451 | 0.420 |
Why?
|
| Research Design | 10 | 2024 | 6210 | 0.410 |
Why?
|
| Autistic Disorder | 3 | 2022 | 1239 | 0.410 |
Why?
|
| Resilience, Psychological | 4 | 2020 | 807 | 0.380 |
Why?
|
| Counseling | 1 | 2019 | 1553 | 0.370 |
Why?
|
| Antipsychotic Agents | 5 | 2018 | 3078 | 0.370 |
Why?
|
| Taurochenodeoxycholic Acid | 2 | 2020 | 35 | 0.360 |
Why?
|
| Caregivers | 6 | 2022 | 2302 | 0.360 |
Why?
|
| Relaxation Therapy | 3 | 2023 | 181 | 0.350 |
Why?
|
| Phenylbutyrates | 2 | 2020 | 72 | 0.350 |
Why?
|
| Metformin | 4 | 2019 | 908 | 0.340 |
Why?
|
| Humans | 179 | 2024 | 767040 | 0.330 |
Why?
|
| Acupuncture | 2 | 2006 | 90 | 0.320 |
Why?
|
| Male | 121 | 2024 | 364203 | 0.320 |
Why?
|
| Mexiletine | 2 | 2020 | 30 | 0.320 |
Why?
|
| Female | 129 | 2024 | 396660 | 0.320 |
Why?
|
| Quinidine | 2 | 2018 | 52 | 0.300 |
Why?
|
| Dextromethorphan | 2 | 2018 | 37 | 0.300 |
Why?
|
| Deglutition Disorders | 3 | 2019 | 640 | 0.290 |
Why?
|
| Health Status | 2 | 2017 | 4091 | 0.280 |
Why?
|
| Neuroprotective Agents | 3 | 2020 | 956 | 0.280 |
Why?
|
| Speech Disorders | 2 | 2019 | 178 | 0.280 |
Why?
|
| Thiazoles | 2 | 2018 | 1530 | 0.280 |
Why?
|
| Child Development Disorders, Pervasive | 4 | 2017 | 597 | 0.280 |
Why?
|
| Constipation | 5 | 2022 | 570 | 0.270 |
Why?
|
| Thalassemia | 4 | 2009 | 267 | 0.270 |
Why?
|
| Neurofibromatosis 2 | 2 | 2020 | 387 | 0.270 |
Why?
|
| Child | 50 | 2022 | 80771 | 0.260 |
Why?
|
| Adolescent | 49 | 2022 | 89046 | 0.250 |
Why?
|
| Polysomnography | 4 | 2022 | 1868 | 0.250 |
Why?
|
| Single-Blind Method | 8 | 2023 | 1587 | 0.250 |
Why?
|
| Videoconferencing | 4 | 2020 | 209 | 0.250 |
Why?
|
| Sample Size | 2 | 2019 | 845 | 0.250 |
Why?
|
| Caffeine | 2 | 2020 | 703 | 0.250 |
Why?
|
| Acupuncture Therapy | 4 | 2016 | 485 | 0.240 |
Why?
|
| Middle Aged | 72 | 2024 | 223233 | 0.240 |
Why?
|
| Antiparkinson Agents | 2 | 2023 | 184 | 0.240 |
Why?
|
| Anemia, Sickle Cell | 6 | 2015 | 1065 | 0.240 |
Why?
|
| Pilot Projects | 17 | 2024 | 8732 | 0.240 |
Why?
|
| Severity of Illness Index | 14 | 2022 | 15925 | 0.230 |
Why?
|
| Gastrointestinal Diseases | 4 | 2017 | 1205 | 0.230 |
Why?
|
| Treatment Outcome | 36 | 2024 | 65295 | 0.230 |
Why?
|
| Irritable Bowel Syndrome | 3 | 2022 | 454 | 0.230 |
Why?
|
| Schizophrenia | 7 | 2013 | 6977 | 0.230 |
Why?
|
| Adult | 68 | 2024 | 223317 | 0.220 |
Why?
|
| Speech | 2 | 2018 | 555 | 0.210 |
Why?
|
| Delayed Diagnosis | 2 | 2019 | 454 | 0.210 |
Why?
|
| Aged | 53 | 2024 | 171319 | 0.210 |
Why?
|
| Piperazines | 1 | 2013 | 2548 | 0.200 |
Why?
|
| beta-Thalassemia | 3 | 2013 | 234 | 0.200 |
Why?
|
| Adaptation, Psychological | 7 | 2022 | 2662 | 0.200 |
Why?
|
| Feasibility Studies | 6 | 2024 | 5311 | 0.200 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 2 | 2016 | 213 | 0.190 |
Why?
|
| Psychotherapy, Group | 2 | 2016 | 417 | 0.190 |
Why?
|
| Overweight | 4 | 2018 | 2448 | 0.190 |
Why?
|
| Deferoxamine | 3 | 2013 | 155 | 0.190 |
Why?
|
| Health Education | 2 | 2019 | 1058 | 0.190 |
Why?
|
| Patient Selection | 6 | 2024 | 4256 | 0.190 |
Why?
|
| Phenytoin | 1 | 2022 | 189 | 0.190 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2021 | 409 | 0.180 |
Why?
|
| Child, Preschool | 21 | 2022 | 42606 | 0.180 |
Why?
|
| Anticonvulsants | 3 | 2022 | 1921 | 0.180 |
Why?
|
| Iron Chelating Agents | 3 | 2013 | 141 | 0.180 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2018 | 1987 | 0.180 |
Why?
|
| Face | 2 | 2017 | 1029 | 0.180 |
Why?
|
| Muscle Strength Dynamometer | 2 | 2018 | 41 | 0.180 |
Why?
|
| Folic Acid | 3 | 2013 | 1336 | 0.180 |
Why?
|
| Chiropractic | 1 | 2020 | 39 | 0.180 |
Why?
|
| Vital Capacity | 3 | 2019 | 996 | 0.180 |
Why?
|
| Stress, Psychological | 5 | 2022 | 4526 | 0.180 |
Why?
|
| Phenylenediamines | 1 | 2021 | 89 | 0.180 |
Why?
|
| Ferrous Compounds | 1 | 2019 | 40 | 0.170 |
Why?
|
| Carbamates | 1 | 2021 | 191 | 0.160 |
Why?
|
| Alkaloids | 1 | 2020 | 192 | 0.160 |
Why?
|
| Nutritional Status | 3 | 2018 | 1628 | 0.160 |
Why?
|
| Control Groups | 1 | 2019 | 107 | 0.160 |
Why?
|
| Evoked Potentials, Motor | 2 | 2020 | 463 | 0.160 |
Why?
|
| Rectum | 2 | 2016 | 898 | 0.160 |
Why?
|
| Hereditary Sensory and Autonomic Neuropathies | 1 | 2019 | 41 | 0.160 |
Why?
|
| Neurilemmoma | 1 | 2024 | 522 | 0.150 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2019 | 1107 | 0.150 |
Why?
|
| Dental Caries | 1 | 2022 | 429 | 0.150 |
Why?
|
| Alzheimer Disease | 3 | 2023 | 8717 | 0.150 |
Why?
|
| Cerebral Amyloid Angiopathy | 2 | 2015 | 887 | 0.150 |
Why?
|
| Dysarthria | 1 | 2017 | 56 | 0.150 |
Why?
|
| Myography | 1 | 2018 | 111 | 0.140 |
Why?
|
| Stereotyped Behavior | 1 | 2018 | 133 | 0.140 |
Why?
|
| World Health Organization | 1 | 2024 | 1327 | 0.140 |
Why?
|
| Creatine | 1 | 2019 | 424 | 0.140 |
Why?
|
| Depression | 6 | 2022 | 8234 | 0.140 |
Why?
|
| Pain Measurement | 3 | 2024 | 3584 | 0.140 |
Why?
|
| Bone Density | 5 | 2018 | 3573 | 0.140 |
Why?
|
| Antioxidants | 2 | 2016 | 1671 | 0.140 |
Why?
|
| Bone and Bones | 3 | 2017 | 2587 | 0.140 |
Why?
|
| Fractals | 1 | 2017 | 124 | 0.140 |
Why?
|
| Longitudinal Studies | 10 | 2020 | 14766 | 0.140 |
Why?
|
| Schizophrenic Psychology | 3 | 2013 | 1647 | 0.140 |
Why?
|
| Deglutition | 1 | 2018 | 208 | 0.130 |
Why?
|
| Compulsive Behavior | 1 | 2017 | 117 | 0.130 |
Why?
|
| Deafness | 1 | 2020 | 460 | 0.130 |
Why?
|
| General Adaptation Syndrome | 1 | 2016 | 7 | 0.130 |
Why?
|
| Spinal Cord | 2 | 2022 | 1811 | 0.130 |
Why?
|
| Superoxide Dismutase | 2 | 2022 | 596 | 0.130 |
Why?
|
| Public Housing | 1 | 2017 | 140 | 0.130 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2016 | 149 | 0.130 |
Why?
|
| Motor Neurons | 1 | 2021 | 869 | 0.130 |
Why?
|
| alpha-Synuclein | 1 | 2022 | 773 | 0.130 |
Why?
|
| Motor Skills | 2 | 2017 | 521 | 0.130 |
Why?
|
| Laxatives | 1 | 2016 | 95 | 0.130 |
Why?
|
| Oral Health | 1 | 2021 | 493 | 0.120 |
Why?
|
| Job Application | 1 | 2015 | 38 | 0.120 |
Why?
|
| Remission, Spontaneous | 1 | 2015 | 384 | 0.120 |
Why?
|
| Neural Stem Cells | 1 | 2022 | 895 | 0.120 |
Why?
|
| Pharmacogenetics | 1 | 2019 | 682 | 0.120 |
Why?
|
| Tamoxifen | 1 | 2019 | 966 | 0.120 |
Why?
|
| Cephalometry | 1 | 2016 | 380 | 0.120 |
Why?
|
| Serine | 1 | 2019 | 828 | 0.120 |
Why?
|
| Mind-Body Relations, Metaphysical | 1 | 2014 | 34 | 0.120 |
Why?
|
| Hydrocortisone | 3 | 2016 | 1840 | 0.120 |
Why?
|
| Young Adult | 18 | 2024 | 59980 | 0.120 |
Why?
|
| Independent Living | 1 | 2019 | 584 | 0.120 |
Why?
|
| Isothiocyanates | 1 | 2014 | 48 | 0.120 |
Why?
|
| Chorionic Villi Sampling | 1 | 2014 | 35 | 0.120 |
Why?
|
| Parents | 6 | 2022 | 3594 | 0.120 |
Why?
|
| Health | 1 | 2017 | 398 | 0.120 |
Why?
|
| Early Diagnosis | 1 | 2019 | 1188 | 0.120 |
Why?
|
| Hirschsprung Disease | 1 | 2016 | 164 | 0.110 |
Why?
|
| Critical Illness | 2 | 2020 | 2753 | 0.110 |
Why?
|
| Follow-Up Studies | 16 | 2020 | 39317 | 0.110 |
Why?
|
| Polydactyly | 1 | 2014 | 57 | 0.110 |
Why?
|
| Inservice Training | 1 | 2016 | 374 | 0.110 |
Why?
|
| Electric Impedance | 1 | 2018 | 792 | 0.110 |
Why?
|
| Anxiety | 4 | 2020 | 4670 | 0.110 |
Why?
|
| Skin Neoplasms | 2 | 2024 | 5859 | 0.110 |
Why?
|
| Social Behavior | 2 | 2018 | 1147 | 0.110 |
Why?
|
| Patient Compliance | 2 | 2015 | 2697 | 0.110 |
Why?
|
| Child Behavior | 2 | 2022 | 864 | 0.110 |
Why?
|
| Nutritional Requirements | 1 | 2015 | 279 | 0.110 |
Why?
|
| Corpus Striatum | 1 | 2020 | 1217 | 0.110 |
Why?
|
| Drug Discovery | 1 | 2021 | 1068 | 0.110 |
Why?
|
| Postural Balance | 2 | 2016 | 638 | 0.110 |
Why?
|
| Benzhydryl Compounds | 2 | 2011 | 944 | 0.110 |
Why?
|
| Communication | 2 | 2018 | 3904 | 0.110 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2013 | 57 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2019 | 638 | 0.110 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2011 | 276 | 0.100 |
Why?
|
| Unnecessary Procedures | 1 | 2016 | 412 | 0.100 |
Why?
|
| Siderophores | 1 | 2013 | 61 | 0.100 |
Why?
|
| Personnel Selection | 1 | 2015 | 201 | 0.100 |
Why?
|
| Axons | 1 | 2020 | 1675 | 0.100 |
Why?
|
| Blood Volume Determination | 1 | 2012 | 40 | 0.100 |
Why?
|
| Memory Disorders | 2 | 2010 | 1193 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2023 | 10393 | 0.100 |
Why?
|
| Blood Pressure | 4 | 2018 | 8531 | 0.100 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 1396 | 0.100 |
Why?
|
| Cerebral Cortex | 2 | 2021 | 5754 | 0.100 |
Why?
|
| Levodopa | 2 | 2023 | 221 | 0.100 |
Why?
|
| Comorbidity | 4 | 2022 | 10582 | 0.100 |
Why?
|
| Hearing Loss | 1 | 2019 | 785 | 0.100 |
Why?
|
| Hypokalemia | 1 | 2013 | 152 | 0.100 |
Why?
|
| Micronutrients | 1 | 2015 | 390 | 0.100 |
Why?
|
| Skull | 1 | 2016 | 819 | 0.100 |
Why?
|
| Gait | 1 | 2017 | 823 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 5 | 2013 | 6023 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 1804 | 0.100 |
Why?
|
| Weight Gain | 2 | 2019 | 2360 | 0.090 |
Why?
|
| Gout | 1 | 2018 | 620 | 0.090 |
Why?
|
| Maternal Age | 1 | 2014 | 804 | 0.090 |
Why?
|
| Serotonin | 1 | 2016 | 1045 | 0.090 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2016 | 746 | 0.090 |
Why?
|
| Fatigue | 3 | 2017 | 1556 | 0.090 |
Why?
|
| Antimetabolites | 1 | 2011 | 128 | 0.090 |
Why?
|
| Hyperkalemia | 1 | 2013 | 233 | 0.090 |
Why?
|
| Hypoglycemic Agents | 3 | 2019 | 3108 | 0.090 |
Why?
|
| Blood Volume | 1 | 2012 | 543 | 0.090 |
Why?
|
| Cycloserine | 1 | 2011 | 118 | 0.090 |
Why?
|
| C-Reactive Protein | 2 | 2021 | 3851 | 0.090 |
Why?
|
| Psychotherapy | 1 | 2019 | 1653 | 0.090 |
Why?
|
| Pelvic Organ Prolapse | 1 | 2012 | 116 | 0.090 |
Why?
|
| Ovarian Hyperstimulation Syndrome | 1 | 2010 | 47 | 0.090 |
Why?
|
| Educational Measurement | 1 | 2017 | 1259 | 0.090 |
Why?
|
| Posture | 1 | 2014 | 956 | 0.090 |
Why?
|
| Sickness Impact Profile | 1 | 2011 | 299 | 0.090 |
Why?
|
| Colon, Sigmoid | 1 | 2010 | 124 | 0.090 |
Why?
|
| Epistasis, Genetic | 1 | 2012 | 353 | 0.090 |
Why?
|
| Stroke | 5 | 2015 | 9746 | 0.090 |
Why?
|
| Vitamin B 12 | 1 | 2013 | 529 | 0.090 |
Why?
|
| Embryo Transfer | 2 | 2011 | 527 | 0.090 |
Why?
|
| Cross-Sectional Studies | 11 | 2022 | 26325 | 0.080 |
Why?
|
| Kluver-Bucy Syndrome | 1 | 2009 | 9 | 0.080 |
Why?
|
| Outpatients | 3 | 2017 | 1600 | 0.080 |
Why?
|
| AIDS Vaccines | 1 | 2016 | 900 | 0.080 |
Why?
|
| Psychopathology | 1 | 2012 | 434 | 0.080 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2010 | 122 | 0.080 |
Why?
|
| Clozapine | 2 | 2011 | 509 | 0.080 |
Why?
|
| Bayes Theorem | 3 | 2023 | 2353 | 0.080 |
Why?
|
| Tibia | 2 | 2017 | 1075 | 0.080 |
Why?
|
| Hypertension | 2 | 2006 | 8615 | 0.080 |
Why?
|
| Embryo Implantation | 1 | 2011 | 272 | 0.080 |
Why?
|
| Delusions | 1 | 2011 | 300 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2019 | 2647 | 0.080 |
Why?
|
| Intelligence Tests | 2 | 2022 | 504 | 0.080 |
Why?
|
| Cryopreservation | 2 | 2011 | 727 | 0.080 |
Why?
|
| Long QT Syndrome | 1 | 2013 | 473 | 0.080 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2015 | 2441 | 0.080 |
Why?
|
| Infertility, Female | 1 | 2014 | 763 | 0.080 |
Why?
|
| Community Health Services | 1 | 2014 | 659 | 0.080 |
Why?
|
| Vitamin B Complex | 1 | 2011 | 299 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2010 | 329 | 0.080 |
Why?
|
| Cerebrovascular Disorders | 1 | 2015 | 1478 | 0.080 |
Why?
|
| Dementia | 1 | 2023 | 2741 | 0.080 |
Why?
|
| Organs at Risk | 1 | 2010 | 367 | 0.080 |
Why?
|
| Chronic Disease | 4 | 2019 | 9362 | 0.080 |
Why?
|
| Cytokines | 2 | 2021 | 7446 | 0.080 |
Why?
|
| Circumcision, Male | 1 | 2010 | 148 | 0.080 |
Why?
|
| Career Choice | 1 | 2015 | 769 | 0.080 |
Why?
|
| Neural Conduction | 2 | 2020 | 442 | 0.080 |
Why?
|
| Seizures | 2 | 2020 | 2996 | 0.080 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2010 | 260 | 0.080 |
Why?
|
| Carbamazepine | 2 | 2022 | 224 | 0.080 |
Why?
|
| Drug Combinations | 3 | 2020 | 2086 | 0.080 |
Why?
|
| Polymorphism, Genetic | 3 | 2019 | 4247 | 0.080 |
Why?
|
| Memory | 1 | 2018 | 2192 | 0.080 |
Why?
|
| Models, Cardiovascular | 1 | 2013 | 978 | 0.070 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2008 | 41 | 0.070 |
Why?
|
| Time Factors | 9 | 2023 | 40154 | 0.070 |
Why?
|
| Migraine Disorders | 1 | 2020 | 1712 | 0.070 |
Why?
|
| Age Factors | 9 | 2017 | 18401 | 0.070 |
Why?
|
| Enteral Nutrition | 1 | 2014 | 802 | 0.070 |
Why?
|
| Pyridones | 1 | 2013 | 819 | 0.070 |
Why?
|
| Oxidants | 1 | 2008 | 168 | 0.070 |
Why?
|
| Prospective Studies | 12 | 2020 | 54886 | 0.070 |
Why?
|
| Intention to Treat Analysis | 2 | 2020 | 418 | 0.070 |
Why?
|
| Prenatal Diagnosis | 1 | 2014 | 1271 | 0.070 |
Why?
|
| Poverty | 1 | 2019 | 2719 | 0.070 |
Why?
|
| Genotype | 5 | 2019 | 13035 | 0.070 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2011 | 480 | 0.070 |
Why?
|
| Aged, 80 and over | 11 | 2020 | 59548 | 0.070 |
Why?
|
| Facial Pain | 1 | 2008 | 119 | 0.070 |
Why?
|
| Developmental Disabilities | 1 | 2016 | 1518 | 0.070 |
Why?
|
| Retrospective Studies | 19 | 2023 | 81659 | 0.070 |
Why?
|
| Ambrosia | 1 | 2006 | 6 | 0.070 |
Why?
|
| Hemiplegia | 1 | 2007 | 137 | 0.070 |
Why?
|
| Cognition | 4 | 2018 | 7059 | 0.070 |
Why?
|
| Vitamin D | 2 | 2018 | 3312 | 0.070 |
Why?
|
| Colonoscopy | 1 | 2015 | 1409 | 0.070 |
Why?
|
| Analysis of Variance | 5 | 2016 | 6215 | 0.070 |
Why?
|
| Benzoates | 1 | 2008 | 213 | 0.070 |
Why?
|
| Infant | 10 | 2017 | 36485 | 0.070 |
Why?
|
| Cohort Studies | 12 | 2020 | 41718 | 0.070 |
Why?
|
| Oxidative Stress | 2 | 2016 | 3139 | 0.070 |
Why?
|
| Carcinoma, Papillary | 1 | 2011 | 791 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2017 | 4052 | 0.060 |
Why?
|
| Pollen | 1 | 2006 | 80 | 0.060 |
Why?
|
| Fertilization in Vitro | 2 | 2011 | 1303 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2014 | 1161 | 0.060 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2013 | 1023 | 0.060 |
Why?
|
| Internship and Residency | 2 | 2017 | 5947 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 7848 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 2783 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2009 | 552 | 0.060 |
Why?
|
| Fertility | 1 | 2010 | 771 | 0.060 |
Why?
|
| Self Efficacy | 2 | 2022 | 643 | 0.060 |
Why?
|
| Cognition Disorders | 3 | 2015 | 3968 | 0.060 |
Why?
|
| Pueraria | 1 | 2005 | 13 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2024 | 4054 | 0.060 |
Why?
|
| Bone Diseases | 1 | 2009 | 416 | 0.060 |
Why?
|
| Ferritins | 3 | 2019 | 601 | 0.060 |
Why?
|
| Physical Fitness | 2 | 2023 | 744 | 0.060 |
Why?
|
| Gadolinium | 1 | 2010 | 964 | 0.060 |
Why?
|
| Alcohol Deterrents | 1 | 2005 | 49 | 0.060 |
Why?
|
| Electromyography | 2 | 2020 | 1398 | 0.060 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2009 | 614 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2024 | 1733 | 0.060 |
Why?
|
| Family | 1 | 2015 | 3210 | 0.060 |
Why?
|
| Dendritic Cells | 1 | 2016 | 2745 | 0.060 |
Why?
|
| Absorptiometry, Photon | 3 | 2018 | 1757 | 0.060 |
Why?
|
| Metabolic Diseases | 1 | 2011 | 684 | 0.060 |
Why?
|
| Urinary Bladder | 1 | 2010 | 1155 | 0.060 |
Why?
|
| Paresis | 1 | 2005 | 177 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 4210 | 0.060 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2010 | 562 | 0.060 |
Why?
|
| Growth Disorders | 1 | 2009 | 635 | 0.060 |
Why?
|
| United States | 10 | 2024 | 72971 | 0.060 |
Why?
|
| Endpoint Determination | 2 | 2022 | 592 | 0.060 |
Why?
|
| Biopsy | 1 | 2016 | 6777 | 0.060 |
Why?
|
| Asthma | 3 | 2008 | 6268 | 0.060 |
Why?
|
| Hydrazones | 1 | 2024 | 105 | 0.060 |
Why?
|
| Pain | 3 | 2009 | 5101 | 0.060 |
Why?
|
| Cerebral Angiography | 1 | 2009 | 1263 | 0.060 |
Why?
|
| Intensive Care Units | 3 | 2022 | 3797 | 0.060 |
Why?
|
| Heart Failure | 3 | 2013 | 11877 | 0.060 |
Why?
|
| Muscle Strength | 2 | 2019 | 640 | 0.060 |
Why?
|
| Cerebral Hemorrhage | 1 | 2015 | 2655 | 0.050 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2023 | 25 | 0.050 |
Why?
|
| Low Back Pain | 1 | 2012 | 989 | 0.050 |
Why?
|
| Sex Factors | 5 | 2020 | 10622 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2021 | 10748 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 4968 | 0.050 |
Why?
|
| Radiation Injuries | 1 | 2010 | 1196 | 0.050 |
Why?
|
| Case-Control Studies | 5 | 2020 | 22254 | 0.050 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2016 | 2538 | 0.050 |
Why?
|
| Brachytherapy | 1 | 2010 | 1220 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2019 | 18063 | 0.050 |
Why?
|
| Phytotherapy | 1 | 2005 | 298 | 0.050 |
Why?
|
| Heterozygote | 2 | 2020 | 2794 | 0.050 |
Why?
|
| Mental Health | 1 | 2017 | 3272 | 0.050 |
Why?
|
| Canada | 2 | 2020 | 2127 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2019 | 456 | 0.050 |
Why?
|
| Triazoles | 1 | 2008 | 903 | 0.050 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 1895 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2011 | 1424 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 2420 | 0.050 |
Why?
|
| Chest Pain | 2 | 2007 | 1101 | 0.050 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2022 | 66 | 0.050 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2020 | 4629 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2015 | 36582 | 0.050 |
Why?
|
| Psychotic Disorders | 3 | 2012 | 3275 | 0.050 |
Why?
|
| Community-Based Participatory Research | 1 | 2024 | 223 | 0.050 |
Why?
|
| Neuropsychological Tests | 2 | 2013 | 7121 | 0.050 |
Why?
|
| Neurofilament Proteins | 1 | 2024 | 335 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2015 | 3886 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2014 | 3207 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2017 | 5098 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2015 | 3446 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 2930 | 0.050 |
Why?
|
| Glutamate Carboxypeptidase II | 2 | 2013 | 90 | 0.050 |
Why?
|
| Carbon Dioxide | 1 | 2006 | 1137 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 2971 | 0.050 |
Why?
|
| Brain Neoplasms | 3 | 2020 | 9108 | 0.050 |
Why?
|
| Weight Loss | 1 | 2013 | 2716 | 0.050 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2023 | 242 | 0.050 |
Why?
|
| Morpholines | 1 | 2024 | 584 | 0.050 |
Why?
|
| Tremor | 1 | 2022 | 196 | 0.050 |
Why?
|
| Phenobarbital | 1 | 2022 | 192 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2014 | 6513 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2016 | 12793 | 0.050 |
Why?
|
| Diet | 2 | 2018 | 8089 | 0.050 |
Why?
|
| Manipulation, Spinal | 1 | 2020 | 21 | 0.040 |
Why?
|
| Central Nervous System Stimulants | 1 | 2009 | 1168 | 0.040 |
Why?
|
| Disease-Free Survival | 4 | 2013 | 6844 | 0.040 |
Why?
|
| Survivors | 2 | 2021 | 2381 | 0.040 |
Why?
|
| Xanthines | 1 | 2020 | 121 | 0.040 |
Why?
|
| Theophylline | 1 | 2020 | 133 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2012 | 2811 | 0.040 |
Why?
|
| Upper Extremity | 1 | 2005 | 684 | 0.040 |
Why?
|
| Body Weight | 1 | 2011 | 4627 | 0.040 |
Why?
|
| Median Nerve | 1 | 2020 | 131 | 0.040 |
Why?
|
| Interleukin-2 | 2 | 2022 | 1894 | 0.040 |
Why?
|
| Seasons | 1 | 2006 | 1523 | 0.040 |
Why?
|
| Oral Hygiene | 1 | 2021 | 132 | 0.040 |
Why?
|
| Electrodiagnosis | 1 | 2020 | 149 | 0.040 |
Why?
|
| Brain Infarction | 1 | 2002 | 285 | 0.040 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 2019 | 30 | 0.040 |
Why?
|
| Intracranial Aneurysm | 1 | 2009 | 1271 | 0.040 |
Why?
|
| Housing for the Elderly | 1 | 2019 | 17 | 0.040 |
Why?
|
| Vitamin D Deficiency | 1 | 2009 | 1389 | 0.040 |
Why?
|
| Prognosis | 5 | 2024 | 29963 | 0.040 |
Why?
|
| Social Support | 1 | 2009 | 2192 | 0.040 |
Why?
|
| Antihypertensive Agents | 2 | 2006 | 2030 | 0.040 |
Why?
|
| Motor Cortex | 1 | 2007 | 1005 | 0.040 |
Why?
|
| Cocaine | 1 | 2004 | 944 | 0.040 |
Why?
|
| Registries | 1 | 2015 | 8351 | 0.040 |
Why?
|
| Viral Load | 1 | 2008 | 3385 | 0.040 |
Why?
|
| ROC Curve | 2 | 2017 | 3618 | 0.040 |
Why?
|
| Statistics as Topic | 2 | 2019 | 2350 | 0.040 |
Why?
|
| Epilepsy | 2 | 2016 | 3317 | 0.040 |
Why?
|
| Dental Care | 1 | 2022 | 285 | 0.040 |
Why?
|
| Linear Models | 4 | 2011 | 5875 | 0.040 |
Why?
|
| Serine C-Palmitoyltransferase | 1 | 2019 | 41 | 0.040 |
Why?
|
| Muscles | 1 | 2023 | 1576 | 0.040 |
Why?
|
| Brain Ischemia | 1 | 2012 | 3001 | 0.040 |
Why?
|
| Speech Therapy | 1 | 2019 | 58 | 0.040 |
Why?
|
| Communication Aids for Disabled | 1 | 2019 | 56 | 0.040 |
Why?
|
| Inpatients | 1 | 2010 | 2563 | 0.040 |
Why?
|
| Time | 1 | 2020 | 551 | 0.040 |
Why?
|
| Disability Evaluation | 2 | 2019 | 1829 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2024 | 718 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2019 | 3232 | 0.040 |
Why?
|
| Reproducibility of Results | 5 | 2016 | 20169 | 0.040 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2010 | 2038 | 0.040 |
Why?
|
| Exercise | 3 | 2023 | 5954 | 0.040 |
Why?
|
| Mental Recall | 1 | 2004 | 1218 | 0.040 |
Why?
|
| Placebos | 2 | 2014 | 1660 | 0.040 |
Why?
|
| Drug Therapy, Combination | 3 | 2013 | 6310 | 0.040 |
Why?
|
| Activities of Daily Living | 2 | 2023 | 2429 | 0.040 |
Why?
|
| Pregnancy Rate | 2 | 2011 | 655 | 0.040 |
Why?
|
| Emotions | 2 | 2022 | 2760 | 0.040 |
Why?
|
| Regression Analysis | 3 | 2014 | 6331 | 0.040 |
Why?
|
| HIV Infections | 3 | 2016 | 17542 | 0.040 |
Why?
|
| Mutation | 2 | 2019 | 30211 | 0.040 |
Why?
|
| Asperger Syndrome | 1 | 2017 | 57 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2015 | 4881 | 0.040 |
Why?
|
| Sphingolipids | 1 | 2019 | 177 | 0.030 |
Why?
|
| Kidney Calculi | 1 | 2021 | 458 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 11923 | 0.030 |
Why?
|
| Contrast Media | 1 | 2010 | 5329 | 0.030 |
Why?
|
| Minority Groups | 1 | 2024 | 1214 | 0.030 |
Why?
|
| Radiography, Dental | 1 | 2016 | 48 | 0.030 |
Why?
|
| Predictive Value of Tests | 4 | 2015 | 15424 | 0.030 |
Why?
|
| Heart Defects, Congenital | 1 | 2013 | 4713 | 0.030 |
Why?
|
| Proportional Hazards Models | 4 | 2015 | 12536 | 0.030 |
Why?
|
| Isometric Contraction | 1 | 2017 | 149 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 996 | 0.030 |
Why?
|
| Lung | 1 | 2015 | 10076 | 0.030 |
Why?
|
| Educational Status | 1 | 2024 | 2511 | 0.030 |
Why?
|
| Pregnancy | 5 | 2022 | 30238 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2011 | 6421 | 0.030 |
Why?
|
| Muscle Cramp | 1 | 2016 | 33 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2009 | 3266 | 0.030 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2018 | 228 | 0.030 |
Why?
|
| Parenting | 1 | 2022 | 708 | 0.030 |
Why?
|
| Injections, Intradermal | 1 | 2016 | 116 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2008 | 4405 | 0.030 |
Why?
|
| Malocclusion | 1 | 2016 | 130 | 0.030 |
Why?
|
| Personal Satisfaction | 1 | 2020 | 643 | 0.030 |
Why?
|
| Cross-Over Studies | 2 | 2017 | 2105 | 0.030 |
Why?
|
| Sensitivity and Specificity | 3 | 2017 | 14672 | 0.030 |
Why?
|
| Laboratories | 1 | 2019 | 463 | 0.030 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2016 | 126 | 0.030 |
Why?
|
| Doxorubicin | 2 | 2013 | 2229 | 0.030 |
Why?
|
| Bradycardia | 1 | 2017 | 305 | 0.030 |
Why?
|
| Glioblastoma | 1 | 2010 | 3461 | 0.030 |
Why?
|
| Financing, Government | 1 | 2019 | 473 | 0.030 |
Why?
|
| Endocrine System | 1 | 2016 | 113 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2021 | 2658 | 0.030 |
Why?
|
| Multiple Sclerosis | 1 | 2010 | 3229 | 0.030 |
Why?
|
| Sulfoxides | 1 | 2014 | 47 | 0.030 |
Why?
|
| Paclitaxel | 2 | 2013 | 1728 | 0.030 |
Why?
|
| Prevalence | 5 | 2015 | 15851 | 0.030 |
Why?
|
| Aftercare | 1 | 2021 | 915 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2008 | 4648 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2019 | 891 | 0.030 |
Why?
|
| Alcoholism | 1 | 2005 | 1980 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 11872 | 0.030 |
Why?
|
| Psychometrics | 1 | 2024 | 3060 | 0.030 |
Why?
|
| Organizational Policy | 1 | 2016 | 435 | 0.030 |
Why?
|
| Attention | 1 | 2004 | 2413 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2024 | 2028 | 0.030 |
Why?
|
| Diet Surveys | 1 | 2018 | 1160 | 0.030 |
Why?
|
| Triazines | 1 | 2016 | 311 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2019 | 872 | 0.030 |
Why?
|
| Radius | 1 | 2017 | 443 | 0.030 |
Why?
|
| Diet Records | 1 | 2015 | 425 | 0.030 |
Why?
|
| Glioma | 1 | 2009 | 3502 | 0.030 |
Why?
|
| Risk Factors | 8 | 2020 | 74886 | 0.030 |
Why?
|
| Fractures, Bone | 1 | 2005 | 2062 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 2201 | 0.030 |
Why?
|
| Renal Insufficiency | 2 | 2010 | 812 | 0.030 |
Why?
|
| Valproic Acid | 1 | 2016 | 444 | 0.030 |
Why?
|
| Eating | 1 | 2020 | 1541 | 0.030 |
Why?
|
| PubMed | 1 | 2013 | 129 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2015 | 9660 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2010 | 20741 | 0.030 |
Why?
|
| Lebanon | 1 | 2013 | 246 | 0.030 |
Why?
|
| Group Processes | 1 | 2014 | 225 | 0.030 |
Why?
|
| Logistic Models | 3 | 2013 | 13284 | 0.020 |
Why?
|
| Intelligence | 1 | 2017 | 925 | 0.020 |
Why?
|
| Injections, Spinal | 1 | 2013 | 317 | 0.020 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2012 | 87 | 0.020 |
Why?
|
| Ontario | 1 | 2013 | 403 | 0.020 |
Why?
|
| Reduced Folate Carrier Protein | 1 | 2011 | 9 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2024 | 3044 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2019 | 2721 | 0.020 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2011 | 12 | 0.020 |
Why?
|
| Health Services | 1 | 2017 | 755 | 0.020 |
Why?
|
| Spirometry | 1 | 2015 | 928 | 0.020 |
Why?
|
| North America | 2 | 2005 | 1287 | 0.020 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2011 | 28 | 0.020 |
Why?
|
| Boston | 2 | 2016 | 9360 | 0.020 |
Why?
|
| Infant, Newborn | 5 | 2014 | 26396 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2017 | 2920 | 0.020 |
Why?
|
| Mandible | 1 | 2016 | 748 | 0.020 |
Why?
|
| Fasting | 1 | 2018 | 1607 | 0.020 |
Why?
|
| Immunization | 1 | 2016 | 1218 | 0.020 |
Why?
|
| Age Distribution | 2 | 2009 | 2870 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2016 | 4349 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2019 | 1422 | 0.020 |
Why?
|
| Physical Examination | 1 | 2017 | 1265 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2024 | 2513 | 0.020 |
Why?
|
| Observer Variation | 1 | 2017 | 2616 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2022 | 18330 | 0.020 |
Why?
|
| Medical Order Entry Systems | 1 | 2016 | 523 | 0.020 |
Why?
|
| HIV-1 | 1 | 2008 | 6951 | 0.020 |
Why?
|
| Motivation | 1 | 2021 | 2021 | 0.020 |
Why?
|
| Cardiovascular System | 1 | 2018 | 839 | 0.020 |
Why?
|
| Calcium | 2 | 2018 | 5792 | 0.020 |
Why?
|
| Metabolomics | 1 | 2020 | 1675 | 0.020 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2020 | 1498 | 0.020 |
Why?
|
| Health Behavior | 1 | 2022 | 2650 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2015 | 1830 | 0.020 |
Why?
|
| Checklist | 1 | 2017 | 842 | 0.020 |
Why?
|
| Recovery of Function | 2 | 2013 | 2978 | 0.020 |
Why?
|
| Social Adjustment | 1 | 2012 | 634 | 0.020 |
Why?
|
| Pregnancy Outcome | 2 | 2011 | 2972 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2017 | 1432 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 3804 | 0.020 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2011 | 251 | 0.020 |
Why?
|
| Twins | 1 | 2011 | 341 | 0.020 |
Why?
|
| Accidental Falls | 1 | 2017 | 1079 | 0.020 |
Why?
|
| Urban Population | 1 | 2017 | 2044 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2008 | 5180 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2010 | 876 | 0.020 |
Why?
|
| Somatomedins | 1 | 2009 | 179 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2015 | 848 | 0.020 |
Why?
|
| Executive Function | 1 | 2017 | 1396 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2022 | 3114 | 0.020 |
Why?
|
| Carboplatin | 1 | 2011 | 790 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2013 | 846 | 0.020 |
Why?
|
| Brain | 1 | 2015 | 27163 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 1012 | 0.020 |
Why?
|
| Acupuncture Analgesia | 1 | 2008 | 63 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2009 | 207 | 0.020 |
Why?
|
| Transfection | 1 | 2016 | 5753 | 0.020 |
Why?
|
| Disease Management | 1 | 2019 | 2531 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2016 | 13048 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2021 | 3467 | 0.020 |
Why?
|
| Cell Degranulation | 1 | 2008 | 276 | 0.020 |
Why?
|
| Phenotype | 3 | 2017 | 16718 | 0.020 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2012 | 606 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 2337 | 0.020 |
Why?
|
| Culture | 1 | 2011 | 622 | 0.020 |
Why?
|
| Cerebral Arteries | 1 | 2009 | 490 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2008 | 276 | 0.020 |
Why?
|
| Joints | 1 | 2009 | 324 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2013 | 1873 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2017 | 2232 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2009 | 959 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 800 | 0.020 |
Why?
|
| Growth Hormone | 1 | 2009 | 572 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2009 | 342 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2009 | 15824 | 0.020 |
Why?
|
| Animals | 4 | 2022 | 168965 | 0.020 |
Why?
|
| Health Personnel | 1 | 2020 | 3387 | 0.020 |
Why?
|
| Atmosphere | 1 | 2006 | 32 | 0.020 |
Why?
|
| Social Isolation | 1 | 2009 | 366 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 663 | 0.020 |
Why?
|
| Education | 1 | 2009 | 531 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 3431 | 0.020 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2010 | 456 | 0.020 |
Why?
|
| Energy Intake | 1 | 2014 | 2145 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2016 | 3227 | 0.020 |
Why?
|
| Models, Economic | 1 | 2010 | 719 | 0.020 |
Why?
|
| Cadaver | 1 | 2010 | 1362 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 21178 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2019 | 3618 | 0.020 |
Why?
|
| Natural Language Processing | 1 | 2015 | 1202 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 2227 | 0.020 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2009 | 390 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 2900 | 0.020 |
Why?
|
| Climate | 1 | 2006 | 146 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2009 | 948 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 9245 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2009 | 10092 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2009 | 582 | 0.020 |
Why?
|
| Vagina | 1 | 2010 | 849 | 0.020 |
Why?
|
| Beer | 1 | 2005 | 135 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 2008 | 658 | 0.010 |
Why?
|
| Cholesterol | 1 | 2014 | 2905 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 3552 | 0.010 |
Why?
|
| Family Characteristics | 1 | 2010 | 1002 | 0.010 |
Why?
|
| Muscle Spasticity | 1 | 2005 | 159 | 0.010 |
Why?
|
| Heart Rate | 1 | 2016 | 4209 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2011 | 3621 | 0.010 |
Why?
|
| Siblings | 1 | 2008 | 828 | 0.010 |
Why?
|
| Catheterization | 1 | 2009 | 1430 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2019 | 8068 | 0.010 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2008 | 881 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2010 | 2915 | 0.010 |
Why?
|
| Organ Size | 1 | 2009 | 2264 | 0.010 |
Why?
|
| Vitamin E | 1 | 2008 | 872 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 3700 | 0.010 |
Why?
|
| Rabbits | 1 | 2009 | 4751 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2018 | 14476 | 0.010 |
Why?
|
| Hypogonadism | 1 | 2009 | 805 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2015 | 3561 | 0.010 |
Why?
|
| Memory, Short-Term | 1 | 2009 | 1004 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2009 | 2245 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 2009 | 1804 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5363 | 0.010 |
Why?
|
| Inflammation | 1 | 2022 | 10869 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2011 | 2592 | 0.010 |
Why?
|
| Wakefulness | 1 | 2009 | 1282 | 0.010 |
Why?
|
| Spinal Fractures | 1 | 2009 | 710 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2009 | 2741 | 0.010 |
Why?
|
| Massachusetts | 1 | 2015 | 8890 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2010 | 1677 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 2902 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2017 | 4859 | 0.010 |
Why?
|
| Iron Overload | 1 | 2004 | 245 | 0.010 |
Why?
|
| Endocrine System Diseases | 1 | 2004 | 250 | 0.010 |
Why?
|
| Plant Extracts | 1 | 2005 | 496 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2009 | 1965 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2009 | 1886 | 0.010 |
Why?
|
| Sleep | 1 | 2017 | 4816 | 0.010 |
Why?
|
| Artifacts | 1 | 2009 | 1904 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 4855 | 0.010 |
Why?
|
| Virus Replication | 1 | 2008 | 2457 | 0.010 |
Why?
|
| Task Performance and Analysis | 1 | 2004 | 771 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2001 | 11513 | 0.010 |
Why?
|
| Risk Assessment | 2 | 2013 | 24299 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2008 | 2867 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2008 | 3154 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 2013 | 3934 | 0.010 |
Why?
|
| Hospitalization | 1 | 2020 | 10815 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 8535 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 2009 | 2672 | 0.010 |
Why?
|
| Patient-Centered Care | 1 | 2009 | 1444 | 0.010 |
Why?
|
| Length of Stay | 1 | 2013 | 6489 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2013 | 5618 | 0.010 |
Why?
|
| Range of Motion, Articular | 1 | 2005 | 1597 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2009 | 2800 | 0.010 |
Why?
|
| Neurosurgical Procedures | 1 | 2009 | 2075 | 0.010 |
Why?
|
| Papillomavirus Infections | 1 | 2010 | 1639 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 3370 | 0.010 |
Why?
|
| Incidence | 1 | 2015 | 21526 | 0.010 |
Why?
|
| Survival Rate | 1 | 2011 | 12823 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 5537 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2010 | 3239 | 0.010 |
Why?
|
| Acute Disease | 1 | 2007 | 7236 | 0.010 |
Why?
|
| Cause of Death | 1 | 2007 | 3717 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2010 | 6260 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2011 | 11217 | 0.010 |
Why?
|
| Iron | 1 | 2004 | 1811 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2002 | 1308 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2009 | 4426 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 2004 | 1959 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 8940 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 7435 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 12069 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 16036 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 5886 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 81912 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 12790 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2004 | 2817 | 0.010 |
Why?
|
| Obesity | 1 | 2013 | 13085 | 0.010 |
Why?
|
| Aging | 1 | 2009 | 8729 | 0.010 |
Why?
|
| Recurrence | 1 | 2002 | 8504 | 0.010 |
Why?
|
| Liver | 1 | 2004 | 7578 | 0.000 |
Why?
|